Home        Sitemap        Contact us 
Parkinson's Disease (PD)
 
You are in: » Pipeline  » Targeted Therapeutics  » Neurodegenerative/CNS  » Parkinson's Disease (PD)
 
Parkinson's disease (PD) is the second most common neurodegenerative disorder and is characterized by slow movement, resting tremor, rigidity, bradykinesia and postural instability. To date, there are no neuroprotective agents used clinically for the treatment of PD. It is estimated that 2% of PD patients are afflicted by age 60 and this incidence increases to 5% by age of 80. Over 60,000 Americans are diagnosed with PD each year and over 7-10 million people worldwide are living with PD. In the United States alone PD care is estimated to cost nearly $25 billion per year. Pathogenic mutations in Leucine-Rich Repeat Kinase-2 (LRRK2), primarily at G2019S cause increased kinase activity with auto phosphorylation, suggesting a gain-of-function mechanism. Hence, LRRK2 has emerged as a promising therapeutic target for PD where inhibitors may lead to potential novel neuroprotective agents.

Thus, the goal of ARN-1104 program is to demonstrate the on target LRRK2 G2019 as mouse models and advance the candidate in to IND enabling studies in Q4 2018. Successful completion of these studies would result in the first orally bioavailable, brain penetrant, and neuroprotective LRRK2 inhibitor for PD indication.
 
ARN-1104
The lead candidates ARN-1104 is now advanced into pre-clinical stage of development for Parkinson's disease. ARN-1104 is a orally available small molecule possess promising neuroprotective activity and excellent DMPK/Tox profiles. The company is initiating IND enabling studies in Q4 2018.
 
Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.